Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Drops By 18.6%

Posted by Tyrone Williams on Sep 29th, 2024

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO – Get Free Report) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 131,600 shares, a drop of 18.6% from the August 31st total of 161,600 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average daily volume of 123,400 shares, the days-to-cover ratio is currently 1.1 days.

Telomir Pharmaceuticals Stock Performance

Shares of Telomir Pharmaceuticals stock opened at $6.82 on Friday. The firm’s 50 day simple moving average is $5.07 and its two-hundred day simple moving average is $5.58. Telomir Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $20.72.

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.05) EPS for the quarter.

Institutional Trading of Telomir Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TELO. Suncoast Equity Management purchased a new stake in Telomir Pharmaceuticals in the first quarter valued at $126,000. Bank of New York Mellon Corp acquired a new stake in Telomir Pharmaceuticals during the second quarter worth about $241,000. Finally, Beaird Harris Wealth Management LLC lifted its holdings in Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after acquiring an additional 9,950 shares during the period.

About Telomir Pharmaceuticals

(Get Free Report)

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.